In Cirrhosis, Women Have Worse Frailty Scores Than Men
MONDAY, Jan. 4, 2021 -- Among patients with cirrhosis, women have worse frailty scores than men, which accounts for part of the gender gap in mortality while awaiting liver transplantation, according to a study published online Dec. 30 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2021 Category: Pharmaceuticals Source Type: news

Association between new-onset liver cirrhosis and suicide risk in South Korea: a nationwide cohort study - Jang SY, Rou WS, Kim SH, Lee BS, Eun HS.
Background& Aims: Current evidence suggests that liver cirrhosis (LC) causes severe psychological stress and depression, which are risk factors for suicide. Although previous studies reported the association between LC and suicidal thoughts, little is kno... (Source: SafetyLit)
Source: SafetyLit - December 21, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cirrhosis Cases Rising Among Women in North America
MONDAY, Nov. 23, 2020 -- Cirrhosis disease burden in women has increased substantially since 2000, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held virtually... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Safety, Tolerability of Elbasvir/grazoprevir in Chronic HCV Safety, Tolerability of Elbasvir/grazoprevir in Chronic HCV
This study evaluated the safety and tolerability of the two-drug oral combination of elbasvir and grazoprevir in individuals with HCV genotype 1 or 4, with and without cirrhosis.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 13, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Cirrhosis, Child-Pugh Score Predict ERCP Complications Cirrhosis, Child-Pugh Score Predict ERCP Complications
The risk for complications related to endoscopic retrograde cholangiopancreatography (ERCP) could be elevated in patients with cirrhosis, according to a retrospective study of almost 700 patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Nobel prize in medicine awarded to US-UK trio for work on hepatitis C
Harvey Alter, Michael Houghton, Charles Rice share 10m Swedish kronor prizeTwo Americans and a British scientist have been awarded the Nobel prize in medicine for their groundbreaking work on blood-borne hepatitis, a health problem that causes cirrhosis and liver cancer around the world.Harvey J Alter at the US National Institutes of Health in Maryland, Charles M Rice from Rockefeller University in New York, and Michael Houghton, a British virologist at the University of Alberta in Canada, were honoured for their joint discovery of the hepatitis C virus, a major cause of liver disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 5, 2020 Category: Science Authors: Ian Sample Science editor Tags: Nobel prizes Science UK news Medicine Science prizes People in science Nobel prize in literature Awards and prizes Source Type: news

3 Win Nobel Medicine Prize for Discovering Hepatitis C Virus
(STOCKHOLM) — Americans Harvey J. Alter and Charles M. Rice and British-born scientist Michael Houghton won the Nobel Prize for medicine on Monday for their discovery of the hepatitis C virus, a major source of liver disease that affects millions worldwide. Announcing the prize in Stockholm, the Nobel Committee noted that the trio’s work identified a major source of blood-borne hepatitis that couldn’t be explained by the previously discovered hepatitis A and B viruses. Their work, dating back to the 1970s and 1980s, has helped saved millions of lives, the committee said. “Thanks to their discovery, ...
Source: TIME: Science - October 5, 2020 Category: Science Authors: DAVID KEYTON and FRANK JORDANS / AP Tags: Uncategorized News News Desk wire Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Researchers discover gene that could decrease likelihood of developing alcoholic cirrhosis
(Indiana University School of Medicine) Researchers at Indiana University School of Medicine are learning more about how a person's genes play a role in the possibility they'll suffer from alcoholic cirrhosis with the discovery of a gene that could make the disease less likely. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

Tools Emerging to Predict Liver Failure in Cirrhosis Tools Emerging to Predict Liver Failure in Cirrhosis
Systemic inflammation and portal hypertension can help predict whether a patient hospitalized for acute decompensated cirrhosis will develop acute-on-chronic liver failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New gene associated with reduced risk for cirrhosis
NIH-funded study provides hope for better disease prediction. (Source: NIAAA News)
Source: NIAAA News - August 31, 2020 Category: Addiction Authors: Katherine Source Type: news

New gene associated with reduced risk for cirrhosis
NIH-funded study provides hope for better disease prediction. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 31, 2020 Category: American Health Source Type: news

Depression and anxiety are common among patients with cirrhosis - Hernaez R, Kramer JR, Khan A, Phillips J, McCallister K, Chaffin K, Hernandez AP, Fullington H, Ortiz C, Blackwell JM, Loewen A, Liu Y, Tiro JA, Lee SC, Singal AG.
BACKGROUND AIMS: Depression and anxiety can have negative effects on patients and are important to treat. There have been few studies of their prevalence among patients with cirrhosis. We aimed to characterize the prevalence and risk factors for depression... (Source: SafetyLit)
Source: SafetyLit - August 30, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Fecal Transplant Shows Promise in Reducing Alcohol Craving Fecal Transplant Shows Promise in Reducing Alcohol Craving
Fecal transplantation for end-stage cirrhosis improves microbiome diversity, reduces alcohol cravings, and improves quality of life, a new safety study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

When liver cirrhosis is deadly
(Goethe University Frankfurt) A study by an international team of researchers headed by Professor Jonel Trebicka from the Frankfurt University Hospital and funded by the foundation EF Clif, has discovered which patients are particularly at risk for acute-on-chronic liver failure. With their findings, the scientists have laid the foundation for the development of preventive therapy to prevent acute-on-chronic liver failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 27, 2020 Category: International Medicine & Public Health Source Type: news

Repeat FIB-4 Blood Tests Help Predict Cirrhosis Repeat FIB-4 Blood Tests Help Predict Cirrhosis
The difference between one fibrosis-4 (FIB-4) score and the next can predict risk for severe liver disease, new research shows, and can provide useful information to primary care doctors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Strides Pharma gets USFDA nod for Ursodiol tablets, a liver disease treatment drug
Strides Pharma Science gets an approval from the USFDA to market Ursodiol tablets used for treating primary biliary cirrhosis, a progressive disease of the liver caused by a buildup of bile within the liver. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2020 Category: Pharmaceuticals Source Type: news

TGen review suggests postmenopausal women at risk for nonalcoholic fatty liver disease
(The Translational Genomics Research Institute) NAFLD is the most common cause of liver damage, and can lead to liver cirrhosis and death. It affects nearly 1 in 4 people across the globe. It often is associated with obesity, abnormally high amounts of lipids in the blood, and type 2 diabetes. In the US, the number of NAFLD cases is expected to grow to more than 100 million within the next decade, annually costing an estimated at $292 billion. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2020 Category: International Medicine & Public Health Source Type: news

Resoundant expands its clinical research services
Medical technology company Resoundant is expanding its clinical research services...Read more on AuntMinnie.comRelated Reading: MRI scoring system could predict liver transplant need New MRI contrast material promises earlier liver diagnosis 2D shear-wave elastography diagnoses cirrhosis New AI platform, CT scanner pace GE launches at RSNA 2018 Elastography helps diagnose pediatric liver fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 12, 2020 Category: Radiology Source Type: news

Acute on Chronic Liver Failure From Novel SARS-CoV-2 Acute on Chronic Liver Failure From Novel SARS-CoV-2
The authors report on a case of acute on chronic liver failure caused by SARS-CoV-2 infection in a patient with decompensated alcoholic cirrhosis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Women Suffer Less NAFLD but More Advanced Fibrosis Women Suffer Less NAFLD but More Advanced Fibrosis
Given the higher risk of advanced fibrosis among women compared to men with NAFLD, it is plausible that cirrhosis and its complications may occur with greater frequency among women than in men.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 16, 2020 Category: Gastroenterology Tags: Ob/Gyn & Women ' s Health News Source Type: news

Fat cell hormone boosts potential of stem cell therapy
(Osaka University) Mesenchymal stem cell (MSC) therapy has shown promising results in the treatment of conditions ranging from liver cirrhosis to retinal damage, but results can be variable. Using a mouse heart failure model, researchers led by Osaka University found that levels of a fat cell-derived hormone called adiponectin in the host significantly affect the efficacy of MSC therapy. Administration of a drug that increases adiponectin in combination with MSCs is therefore likely to significantly improve the clinical outcome. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 10, 2020 Category: Biology Source Type: news

Blood tests can predict the risk of liver cirrhosis
(Karolinska Institutet) Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet in Sweden published in the Journal of Hepatology. The risk of liver cirrhosis increases if the levels of this biomarker rise between two testing occasions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 2, 2020 Category: International Medicine & Public Health Source Type: news

Giant leap in diagnosing liver disease
(Salk Institute) A collaborative team of Salk Institute and UC San Diego scientists have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients. The non-invasive method relies on an algorithm to analyze patient stool samples--which contains traces of what lives in the gut--and could lead to improved patient care and treatment outcomes for liver disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2020 Category: Cancer & Oncology Source Type: news

Universal gut microbiome-derived signature predicts cirrhosis
(University of California - San Diego) UC San Diego School of Medicine researchers report that stool microbiomes of NAFLD patients are distinct enough to potentially be used to accurately predict which persons with NAFLD are at greatest risk for having cirrhosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2020 Category: International Medicine & Public Health Source Type: news

Transducer shell improves elastography measurements
A 3D-printed device with built-in pressure sensors that fits around an ultrasound...Read more on AuntMinnie.comRelated Reading: Tongue ultrasound may identify obstructive sleep apnea SWE effectively predicts cirrhosis complications Elastography shows high reproducibility in breast lesions Elastography helps liver transplant patients avoid biopsy Shear-wave elastography tracks effects of knee surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 23, 2020 Category: Radiology Source Type: news

NAFLD Progression Rates to Cirrhosis, Decompensation, Mortality NAFLD Progression Rates to Cirrhosis, Decompensation, Mortality
This study aimed to elucidate the natural history of NAFLD/NASH by evaluating the impact of liver disease severity and comorbid health conditions on risk of mortality and risk of disease progression.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Strength training benefits patients with cirrhosis
(Aarhus University) Three hours of weekly strength training combined with protein supplements leads to both bigger and stronger muscles in patients with cirrhosis. This is shown by a new study from Aarhus University and Aarhus University Hospital. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 11, 2020 Category: Biology Source Type: news

What Causes Free Peritoneal Fluid?
Discussion Peritoneal fluid is normal. It decreases the friction of the peritoneum covering abdominal and pelvic organs and helps to protect them and allow their movement. A normal amount of peritoneal fluid is expected on radiological evaluation. Increased peritoneal fluid is a continuum and is concerning as a wide variety of pathological causes are associated with it such as abdominal trauma and appendicitis. At the far end of the scale is ascites that is the accumulation of free fluid more than 25 ml. It is usually associated with abdominal distension but fluid must accumulate before distension can occur and therefore i...
Source: PediatricEducation.org - June 8, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Women are not more likely to die of cirrhosis than men, despite fewer liver transplants
(Northwestern University) Prior studies suggested women might have higher mortality of cirrhosis of the liver than men. Women are also less likely to receive liver transplantation. But the research was unclear. A comprehensive new Northwestern Medicine study shows women are not more likely to die of liver cirrhosis than men, demonstrating that this liver disease affects men and women similarly. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Factors Impacting Fecal Microbiome in Liver Cirrhosis Factors Impacting Fecal Microbiome in Liver Cirrhosis
This study examined the contribution of medications, diet, and disease severity.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver transplant is associated with sustained improvement in tandem gait and risk of falls - Acharya C, White MB, Fagan A, Sterling RK, Stravitz RT, Puri P, Fuchs M, Luketic V, Sanyal AJ, Wade JB, Gilles H, Heuman DM, Tinsley F, Matherly S, Lee H, Siddiqui MS, Thacker LR, Bajaj JS.
BACKGROUND: Cirrhosis is associated with poor health-related quality of life (HRQOL), cognitive dysfunction (CD), and lack of coordination leading to falls. Tandem gait (TG; heel-toe) can be used to assess coordination. The impact and relationship between ... (Source: SafetyLit)
Source: SafetyLit - May 2, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Sugar, Fat, Alcohol … What’s Worse for the Liver?
This webinar will investigate the increasing mortality rates of liver disease in the UK associated with obesity and the excess consumption of alcohol. It will give an overview of non-alcoholic fatty liver disease (NAFLD), which is now the most common  of liver disease affecting an estimated 25-30% of adults and 10% of children in the UK and worldwide. Both NAFLD and alcohol-related fatty liver can progress to severe liver disease including fibrosis, cirrhosis and hepatocellular carcinoma. The roles of genetics, obesity and dietary patterns i n the development and progression of liver disease will be dis...
Source: The Nutrition Society - April 9, 2020 Category: Nutrition Authors: Jade Mitchell Source Type: news

IFN-free HCV Regimens: Outcomes With Compensated Cirrhosis IFN-free HCV Regimens: Outcomes With Compensated Cirrhosis
This study evaluated the clinical benefit of interferon-free regimens in chronically HCV-infected patients diagnosed with compensated cirrhosis.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Increased Cancer Rates in Patients With Chronic Hepatitis C Increased Cancer Rates in Patients With Chronic Hepatitis C
This study shows an increased rate of several different cancer types in hepatitis C patients compared to those who do not have HCV. How does cirrhosis impact cancer incidence?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Intensive Program Prevents COVID-19 in Patients With Decompensated Cirrhosis Intensive Program Prevents COVID-19 in Patients With Decompensated Cirrhosis
An intensive program implemented in Wuhan, China, prevented COVID-19 in 82 outpatients and 29 inpatients with decompensated cirrhosis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Epclusa Approved for Children With Any Hep C Genotype
FRIDAY, March 20, 2020 -- Epclusa (sofosbuvir and velpatasvir) received approval for a supplemental application to treat hepatitis C virus (HCV) in children without cirrhosis or with mild cirrhosis, the U.S. Food and Drug Administration announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2020 Category: General Medicine Source Type: news

Associatio Between Volume of Fluid Resuscitation and Intubation in High-Risk Patients With Sepsis, Heart Failure, End-Stage Renal Disease, and Cirrhosis
This study was designed to assess the association between 30 mL/kg crystalloids and intubation in patients with sepsis or septic shock and heart failure, end-stage renal disease, or cirrhosis. Method(s): This propensity score-matched retrospective cohort study included patients with sepsis or septic shock admitted to a large medical ICU. Primary exposure was IV fluid volume in the first 6 h following sepsis diagnosis, divided into two cohorts:>= 30 mL/kg (standard group) and (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 13, 2020 Category: Consumer Health News Source Type: news

SWE effectively predicts cirrhosis complications
Shear-wave elastography (SWE) is an effective way to help predict liver-related...Read more on AuntMinnie.comRelated Reading: Elastography shows high reproducibility in breast lesions SWE identifies hydrocephalus in infants Elastography helps liver transplant patients avoid biopsy Shear-wave elastography tracks effects of knee surgery Elastography methods reduce unnecessary breast biopsies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 6, 2020 Category: Radiology Source Type: news

Zydus Cadila gets DCGI nod for world's first drug to treat liver disease
The Ahmedabad-based company said the approved product is the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) which is a progressive disease of the liver. The condition starts with fat accumulation in the liver known as non-alcoholic fatty liver disease and progress to cirrhosis and liver failure. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 4, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma
Basel, 4 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys ® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC). Dr. Amit Singal, Medical Director of the Liver Tumor Program   and Clinical Chief of Pathology at UT Southwestern Medical Center in Dallas, USA, stated, " HCC is the fourth leading cause of cancer-related death worldwide, wit...
Source: Roche Investor Update - March 4, 2020 Category: Pharmaceuticals Source Type: news